SwePub
Sök i LIBRIS databas

  Extended search

onr:"swepub:oai:DiVA.org:uu-424548"
 

Search: onr:"swepub:oai:DiVA.org:uu-424548" > Pharmacodynamics, p...

  • 1 of 1
  • Previous record
  • Next record
  •    To hitlist
LIBRIS Formathandbok  (Information om MARC21)
FältnamnIndikatorerMetadata
00005523naa a2200589 4500
001oai:DiVA.org:uu-424548
003SwePub
008201111s2020 | |||||||||||000 ||eng|
0247 a https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-4245482 URI
0247 a https://doi.org/10.1093/eurheartj/ehz8072 DOI
040 a (SwePub)uu
041 a engb eng
042 9 SwePub
072 7a ref2 swepub-contenttype
072 7a art2 swepub-publicationtype
1001 a Storey, Robert F.u Univ Sheffield, Dept Infect Immun & Cardiovasc Dis, Sheffield, S Yorkshire, England.4 aut
2451 0a Pharmacodynamics, pharmacokinetics, and safety of single-dose subcutaneous administration of selatogrel, a novel P2Y12 receptor antagonist, in patients with chronic coronary syndromes
264 c 2019-11-14
264 1b Oxford University Press (OUP),c 2020
338 a electronic2 rdacarrier
520 a Aims To study the pharmacodynamics and pharmacokinetics of selatogrel, a novel P2Y(12) receptor antagonist for subcutaneous administration, in patients with chronic coronary syndromes (CCS). Methods and results In this double-blind, randomized study of 345 patients with CCS on background oral antiplatelet therapy, subcutaneous selatogrel (8 mg, n = 114; or 16 mg, n = 115) was compared with placebo (n = 116) (ClinicalTrials.gov: NCT03384966). Platelet aggregation was assessed over 24 h (VerifyNow assay) and 8 h (light transmittance aggregometry; LTA). Pharmacodynamic responders were defined as patients having P2Y(12) reaction units (PRU) <100 at 30 min post-dose and lasting >= 3 h. At 30 min post-dose, 89% of patients were responders to selatogrel 8 mg, 90% to selatogrel 16 mg, and 16% to placebo (P < 0.0001). PRU values (mean standard deviation) were 10 +/- 25 (8 mg), 4 +/- 10 (16 mg), and 163 +/- 73 (placebo) at 15 min and remained <100 up to 8 h for both doses, returning to pre-dose or near pre-dose levels by 24 h post-dose. LTA data showed similarly rapid and potent inhibition of platelet aggregation. Selatogrel plasma concentrations peaked similar to 30 min post-dose. Selatogrel was safe and well-tolerated with transient dyspnoea occurring overall in 7% (16/229) of patients (95% confidence interval: 4-11%). Conclusions Selatogrel was rapidly absorbed following subcutaneous administration in CCS patients, providing prompt, potent, and consistent platelet P2Y(12) inhibition sustained for >= 8 h and reversible within 24 h. Further studies of subcutaneous selatogrel are warranted in clinical scenarios where rapid platelet inhibition is desirable.
650 7a MEDICIN OCH HÄLSOVETENSKAPx Klinisk medicinx Kardiologi0 (SwePub)302062 hsv//swe
650 7a MEDICAL AND HEALTH SCIENCESx Clinical Medicinex Cardiac and Cardiovascular Systems0 (SwePub)302062 hsv//eng
653 a Selatogrel
653 a Platelet aggregation
653 a Coronary artery disease
653 a P2Y(12) receptor antagonist
653 a Pharmacodynamics
653 a Pharmacokinetics
7001 a Gurbel, Paul A.u Inova Heart & Vasc Inst, Falls Church, VA USA.4 aut
7001 a ten Berg, Jurrienu St Antonius Hosp, Dept Cardiol, Nieuwegein, Netherlands.4 aut
7001 a Bernaud, Corineu Idorsia Pharmaceut Ltd, Allschwil, Switzerland.4 aut
7001 a Dangas, George D.u Mt Sinai Hosp, Div Cardiol, New York, NY USA.4 aut
7001 a Frenoux, Jean-Marieu Idorsia Pharmaceut Ltd, Allschwil, Switzerland.4 aut
7001 a Gorog, Diana A.u Univ Hertfordshire, Hatfield, Herts, England.;Imperial Coll, Natl Heart & Lung Inst, London, England.4 aut
7001 a Hmissi, Abdelu Idorsia Pharmaceut Ltd, Allschwil, Switzerland.4 aut
7001 a Kunadian, Vijayu Newcastle Univ, Fac Med Sci, Newcastle Upon Tyne, Tyne & Wear, England.;Newcastle Tyne Hosp NHS Fdn Trust, Freeman Hosp, Cardiothorac Ctr, Newcastle Upon Tyne, Tyne & Wear, England.4 aut
7001 a James, Stefan,d 1964-u Uppsala universitet,Uppsala kliniska forskningscentrum (UCR)4 aut0 (Swepub:uu)stjam367
7001 a Tanguay, Jean-Francoisu Univ Montreal, Inst Cardiol Montreal, Dept Med, Montreal, PQ, Canada.4 aut
7001 a Tran, Henryu Inova Heart & Vasc Inst, Falls Church, VA USA.4 aut
7001 a Trenk, Dietmaru Univ Heart Ctr Freiburg Bad Krozingen, Dept Cardiol & Angiol 2, Bad Krozingen, Germany.4 aut
7001 a Ufer, Mikeu Idorsia Pharmaceut Ltd, Allschwil, Switzerland.4 aut
7001 a Van der Harst, Pimu Univ Groningen, Univ Med Ctr Groningen, Dept Cardiol, Groningen, Netherlands.4 aut
7001 a Van't Hof, Arnoud W. J.u Maastricht Univ Med Ctr MUMC, Dept Cardiol, Maastricht, Netherlands.;Zuyderland Med Ctr ZMC, Dept Cardiol, Heerlen, Netherlands.;Isala Hosp, Dept Cardiol, Zwolle, Netherlands.4 aut
7001 a Angiolillo, Dominick J.u Univ Florida, Div Cardiol, Coll Med, Jacksonville, FL USA.4 aut
7102 a Univ Sheffield, Dept Infect Immun & Cardiovasc Dis, Sheffield, S Yorkshire, England.b Inova Heart & Vasc Inst, Falls Church, VA USA.4 org
7730 t European Heart Journald : Oxford University Press (OUP)g 41:33, s. 3132-3140q 41:33<3132-3140x 0195-668Xx 1522-9645
8564 u https://doi.org/10.1093/eurheartj/ehz807y Fulltext
8564 u https://uu.diva-portal.org/smash/get/diva2:1500068/FULLTEXT01.pdfx primaryx Raw objecty fulltext:print
8564 u https://doi.org/10.1093/eurheartj/ehz807
8564 8u https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-424548
8564 8u https://doi.org/10.1093/eurheartj/ehz807

Find in a library

To the university's database

  • 1 of 1
  • Previous record
  • Next record
  •    To hitlist

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Close

Copy and save the link in order to return to this view